A Phase 2, Multi-Center, Platform Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics with Multiple Therapies in Participants with Active Crohn’s Disease or Active Ulcerative Colitis (ASCEND-IBD)
Not yet recruitingCTIS2025-522001-38-00
Mirador Therapeutics Inc.Crohn’s Disease, Ulcerative Colitis
Target: 54Updated: 2025-10-26